FDA Approval Led to More Young Patients Receiving TAVR
FDA Approval Led to More Young Patients Receiving TAVR
Source
JACC — February 11, 2026
• In 2019, the FDA approved TAVR for low-risk patients.
• After this decision, more patients under 65 years began receiving TAVR.
• Many of these patients were lower risk and might previously have undergone surgery (SAVR).
• Short-term results were generally good.
• However, the very youngest patients (<65) showed higher 1-year mortality after adjustment.
• This may reflect more complex disease patterns or hidden risk factors — not necessarily a procedural issue.
• Guidelines still recommend SAVR for patients under 65 years.
• Careful patient selection and long-term follow-up are essential.
Key Point:
The 2019 FDA decision shifted practice toward younger, lower-risk TAVR use — but durability and long-term outcomes remain major considerations.